|
May 6
|
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
|
|
May 2
|
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
|
|
Apr 24
|
Calliditas Therapeutics' 2023 Annual Report Published
|
|
Apr 24
|
Calliditas Announces Positive NefIgArd Open Label Extension Results
|
|
Apr 18
|
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
|
|
Apr 16
|
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
|
|
Apr 9
|
Calliditas Therapeutics to Attend Conferences in April
|
|
Apr 8
|
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
|
|
Apr 8
|
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
|
|
Mar 12
|
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
|
|
Mar 6
|
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
|
|
Dec 20
|
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
|
|
Dec 1
|
Calliditas announces additions to the management team
|
|
Nov 30
|
Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome
|
|
Nov 24
|
Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy
|
|
Nov 7
|
Calliditas to present at upcoming investor conferences
|
|
Nov 7
|
Calliditas Interim Report January - September 2023
|
|
Nov 7
|
Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023
|
|
Jul 6
|
Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?
|